<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87190">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01702051</url>
  </required_header>
  <id_info>
    <org_study_id>43-09/02/2012</org_study_id>
    <nct_id>NCT01702051</nct_id>
  </id_info>
  <brief_title>Extending Indication for Islet Autotransplantation in Pancreatic Surgery</brief_title>
  <acronym>AutoTx</acronym>
  <official_title>Autologous Pancreatic Islet Cell Transplantation for Improved Glycaemic Control After Pancreatectomy: Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministery of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale San Raffaele</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Islet autotransplantation (IAT) is a therapeutic approach used to prevent pancreatogenic
      diabetes or to reduce the severity of diabetes after a major pancreatectomy. Total
      pancreatectomy with IAT is being used almost exclusively for treatment of chronic
      pancreatitis. More recently, indications other than chronic pancreatitis have been reported
      including IAT after extended pancreatectomy performed for the resection of benign tumors of
      the mid-segment of the pancreas or IAT after total pancreatectomy for severe abdominal
      trauma In this study, we study our experience with IAT for the treatment of a broader
      population of patients undergoing pancreatic surgery including subjects with technically
      unfeasible or high risk pancreatic anastomosis during partial pancreatectomy and subjects
      undergoing completion pancreatectomy because of anastomosis leakage after
      pancreatoduodenectomy for nonmalignant or malignant diseases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Beta cell function</measure>
    <time_frame>month 1, 3, 6, 12 and every year up to death</time_frame>
    <safety_issue>No</safety_issue>
    <description>Beta-cell function will be assessed by fasting C peptide, HbA1c,glycaemia, change in average daily insulin requirements, basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the arginine test, beta-score and Transplant Estimated Function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications after pancreatic surgery</measure>
    <time_frame>90 days from discharge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Complications will be defined and graded according to the Novel Grading System classification ( DeOliveira et al 2006). A special emphasis is given to life-threatening and permanently disabling complications.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of each individual postoperative complication</measure>
    <time_frame>90 days from discharge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>death
pancreatic fistula defined according to the International Study Group on Pancreatic Fistula (Bassi C et al 2005)
delayed gastric emptying (DGE) defined according to the International Study Group on Pancreatic Fistula (Wente et al 2007)
intra-abdominal complications
medical complications</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>patients with chronic pancreatitis treated with total or subtotal pancreatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>patients underwent completion pancreatectomy because of anastomotic leak after partial pancreatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>patients underwent pancreatoduodenectomy in which pancreatic anastomosis was made impracticable by technical difficulties and/or high risk of leakage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>patients underwent extensive distal pancreatectomy for pancreatic lesions located at the neck</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, PBMC
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent partial or total pancreatectomy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age

               -  ability to provide written informed consent

               -  fasting glycaemia &lt;126 mg/dl without glucose-lowering medications.

        Exclusion Criteria:

          -  Any medical condition that, in the opinion of the investigator, will interfere with
             the safe completion of the trial

          -  Diagnosis of intraductal papillary mucinous cancer, unless the absence of multifocal
             lesion is demonstrated by endoscopic US

          -  Presence of multifocal or residual disease at the pancreatic margin. If a malignat
             disease is the reason for the surgery, 1 cm of the pancreatic remnant in proximity to
             the pancreatic margin will be resected and sent for immediate pathologic analysis to
             confirm margin negativity and to rule out multifocal tumor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenzo Piemonti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific Institute San Raffaele</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianpaolo Balzano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Scientific Institute San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gianpaolo Balzano, MD</last_name>
    <phone>0226432664</phone>
    <phone_ext>0039</phone_ext>
    <email>balzano.gianpaolo@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paola Maffi, MD</last_name>
    <phone>0226462575</phone>
    <phone_ext>0039</phone_ext>
    <email>maffi.paola@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale San Raffaele (OSR)</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianpaolo Balzano, MD</last_name>
      <phone>0226432664</phone>
      <phone_ext>0039</phone_ext>
      <email>balzano.gianpaolo@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Lorenzo Piemonti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gianpaolo Balzano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paola Maffi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 4, 2012</lastchanged_date>
  <firstreceived_date>October 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scientific Institute San Raffaele</investigator_affiliation>
    <investigator_full_name>Piemonti Lorenzo</investigator_full_name>
    <investigator_title>Director Islet Transplantation Program</investigator_title>
  </responsible_party>
  <keyword>Pancreatogenic diabetes</keyword>
  <keyword>Autologou Islet Transplantation</keyword>
  <keyword>Pancreas</keyword>
  <keyword>Pancreatectomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
